CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
N/A eltrombopag Severe Aplastic Anemia (SAA) Reimburse with clinical criteria and/or conditions Active
Elrexfio elranatamab Relapsed or refractory multiple myeloma Active
Vimizim Elosulfase alfa Mucopolysaccharidosis IVA (Morquio A syndrome) Reimburse with clinical criteria and/or conditions Complete
Vimizim Elosulfase alfa Mucopolysaccharidosis IVA (Morquio A syndrome) Do not list Complete
Cerdelga Eliglustat Gaucher disease Reimburse with clinical criteria and/or conditions Complete
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older Active
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation, 2 years and older Reimburse with clinical criteria and/or conditions Complete
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation, 6 years and older Reimburse with clinical criteria and/or conditions Complete
Trikafta elexacaftor / tezacaftor / ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation Reimburse with clinical criteria and/or conditions Complete
Relpax Eletriptan hydrobromide Migraine Do not list Complete
Last Updated : May 16, 2024